Abstract:
:The narrow therapeutic range and wide interpatient variability in dose requirement make anticoagulation response to coumarin derivatives unpredictable. As a result, patients require frequent monitoring to avert adverse effects and maintain therapeutic efficacy. Polymorphisms in VKORC1 and CYP2C9 jointly account for about 40% of the interindividual variability in dose requirements. To date, several pharmacogenetic-guided dosing algorithms for coumarin derivatives, predominately for warfarin, have been developed. However, the potential benefit of these dosing algorithms in terms of their safety and clinical utility has not been adequately investigated in randomized settings. The European Pharmacogenetics of Anticoagulant Therapy (EU-PACT) trial will assess, in a single-blinded and randomized controlled trial with a follow-up period of 3 months, the safety and clinical utility of genotype-guided dosing in daily practice for the three main coumarin derivatives used in Europe. The primary outcome measure is the percentage time in the therapeutic range for international normalized ratio. This report describes the design and protocol for the trial.
journal_name
Pharmacogenomicsjournal_title
Pharmacogenomicsauthors
van Schie RM,Wadelius MI,Kamali F,Daly AK,Manolopoulos VG,de Boer A,Barallon R,Verhoef TI,Kirchheiner J,Haschke-Becher E,Briz M,Rosendaal FR,Redekop WK,Pirmohamed M,Maitland van der Zee AHdoi
10.2217/pgs.09.125subject
Has Abstractpub_date
2009-10-01 00:00:00pages
1687-95issue
10eissn
1462-2416issn
1744-8042journal_volume
10pub_type
杂志文章,多中心研究,随机对照试验相关文献
PHARMACOGENOMICS文献大全abstract::Clozapine is the only effective antipsychotic for treatment-resistant schizophrenia but remains widely under prescribed, at least in part due to its potential to cause agranulocytosis and neutropenia. In this article, we provide an overview of the current understanding of the genetics of clozapine-associated agranuloc...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.2217/pgs-2018-0188
更新日期:2019-03-01 00:00:00
abstract::Multiple sclerosis (MS) is a condition of the CNS marked by inflammation and neurodegeneration. Interferon (IFN)-beta was the first, and still is the main, immunomodulatory treatment for MS. Its clinical efficacy is limited, and a proportion of patients, ranging between 20-55%, do not respond to the therapy. Identific...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.2217/pgs.10.108
更新日期:2010-08-01 00:00:00
abstract::Recently, the USA FDA has made a labeling change to the drug information contained in carbamazepine. Owing to recent data implicating the HLA allele B*1502 as a marker for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese, the FDA recommends genotyping all Asians for the alle...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/14622416.9.10.1543
更新日期:2008-10-01 00:00:00
abstract::Skeletal muscle toxicity is the primary adverse effect of statins. In this review, we summarize current knowledge regarding the genetic and nongenetic determinants of risk for statin induced myopathy. Many genetic factors were initially identified through candidate gene association studies limited to pharmacokinetic (...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.2217/pgs.12.11
更新日期:2012-04-01 00:00:00
abstract::The value of high-throughput genomic research is dramatically enhanced by association with key patient data. These data are generally available but of disparate quality and not typically directly associated. A system that could bring these disparate data sources into a common resource connected with functional genomic...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.1517/14622416.3.5.651
更新日期:2002-09-01 00:00:00
abstract:OBJECTIVES:In an attempt to elucidate the relationship between biomarkers of tumor hypoxia, glycolysis and angiogenesis, we tested the hypothesis that intratumoral gene expression of the hypoxia response (hypoxia inducible factor [HIF1 alpha and 2 alpha]), glycolysis (lactate dehydrogenase A [LDHA]), glucose metabolism...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/14622416.8.12.1705
更新日期:2007-12-01 00:00:00
abstract:AIM:A population pharmacokinetic (PPK) analysis was conducted to describe the influence of GSTA1 polymorphisms on intravenous busulfan in adults undergoing allogeneic hematopoietic stem cell transplantation. PATIENTS & METHODS:A PPK model was developed from 36 patients by a one-compartment model with first-order elimi...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.15.98
更新日期:2015-01-01 00:00:00
abstract:AIM:Hemoglobinopathies exhibit a remarkable phenotypic diversity that restricts any safe association between molecular pathology and clinical outcomes. PATIENTS & METHODS:Herein, we explored the role of genes involved in the nitric oxide biosynthesis and signaling pathway, implicated in the increase of fetal hemoglobi...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.16.1
更新日期:2016-03-01 00:00:00
abstract::Genome-wide association studies (GWAS) allow the finding of genetic variants associated with several traits. Regarding ovarian cancer (OC), 15 GWAS have been conducted since 2009, with the discovery of 49 SNPs associated with disease susceptibility and 46 with impact in the clinical outcome of patients (p < 5.00 × 10-...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.2217/pgs-2017-0108
更新日期:2017-11-01 00:00:00
abstract::The ultrarapid CYP2D6 metabolizer (UM) phenotype is caused by CYP2D6 gene duplications in some, but not all, UM individuals. CYP2D6 and the adjacent pseudogene CYP2D7 are highly homologous; however, CYP2D7 harbors a premature stop codon, which is absent in carriers of the rare CYP2D7 variant rs530303678. We addressed ...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs-2018-0065
更新日期:2018-08-01 00:00:00
abstract:AIM:To investigate the role of genetic polymorphisms in glutamatergic and GABAergic genes and their interactions with environmental stressors in antidepressant response. METHODS:A set of 114 SNPs of 34 glutamatergic and GABAergic genes, mainly in promoter and coding regions, were genotyped in 281 Chinese Han major dep...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.13.1
更新日期:2013-02-01 00:00:00
abstract:AIMS:Bipolar disorder (BD) is a lifelong psychiatric illness characterized by manic and depressive episodes affecting 1-5% of the general population. Among mood-stabilizing treatments, lithium represents the mainstay in the therapeutic management of BD. However, besides the relatively high rate of excellent responders,...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.11.102
更新日期:2011-11-01 00:00:00
abstract::Recent years have seen great advances in our understanding of genetic contributors to drug response. Drug discovery and development around targeted genetic (somatic) mutations has led to a number of new drugs with genetic indications, particularly for the treatment of cancers. Our knowledge of genetic contributors to ...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.13.52
更新日期:2013-05-01 00:00:00
abstract::HER2 upregulation is related with poor outcome in many tumor types. Whereas anti-HER2 treatment is the standard approach as adjuvant therapy in HER2-overexpressing breast cancer, the frequent relapses reinforce the need for alternative treatments. Here we used next-generation sequencing (NGS) to evaluate miRNAs and ci...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs-2018-0182
更新日期:2019-05-01 00:00:00
abstract::Type B adverse drug reactions (ADRs) are often serious, limit the usefulness of drugs that are otherwise effective, and increase the risks of drug development as they often lead to postmarketing withdrawal. There is evidence that susceptibility to at least some Type B ADRs is under strong genetic influence. Identifyin...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.2217/14622416.7.4.633
更新日期:2006-06-01 00:00:00
abstract:BACKGROUND:Clobazam-induced adverse reactions have been reported in cases with CYP2C19 defective allele(s). However, the relevance of the CYP2C19 genotypes to clobazam therapy remains to be clarified. METHODS:The association between CYP2C19 genotypes and the antiepileptic and adverse effects of clobazam was retrospect...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/14622416.9.5.527
更新日期:2008-05-01 00:00:00
abstract::We report the case of a patient bearing a T315I-mutant chronic myeloid leukemia resistant to nilotinib, successfully treated with omacetaxine and then with dasatinib. After 9 months of nilotinib, the patient achieved a major molecular response but relapsed 3 months later due to the T315I mutation. Because third-genera...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.15.25
更新日期:2015-01-01 00:00:00
abstract::After a 1-day advanced course on systems biology, the main themes of this 3-day colloquium were developed: from systems biology to systems medicine with special applications to cancer; pharmacogenomics in drug discovery and clinical application; and epigenomics and genome-wide association studies in cardiovascular dis...
journal_title:Pharmacogenomics
pub_type:
doi:10.2217/pgs.13.201
更新日期:2013-12-01 00:00:00
abstract::Interindividual variability in drug response and the emergence of adverse drug effects are the main causes of treatment failure in cancer therapy. Functional membrane drug transporters play important roles in altering pharmacokinetic profile, resistance to treatment, toxicity and patient survival. Pharmacogenetic stud...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.2217/pgs.12.165
更新日期:2012-12-01 00:00:00
abstract::Toxicogenomics is, arguably, the most exciting endeavor to better understand and/or predict the toxicity of drugs during their development, using technologies such as gene-expression microarrays. Through much of its (sometimes overzealous) build-up, toxicogenomics has found a natural niche as a bioinformatics and/or p...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.2217/14622416.8.8.1081
更新日期:2007-08-01 00:00:00
abstract::Aim: The influence of variants in pharmacokinetics-related genes on long-term exposure to tacrolimus (TAC)-based therapy and clinical outcomes was investigated. Patients & methods: Brazilian kidney recipients were treated with TAC combined with everolimus (n = 178) or mycophenolate sodium (n = 97). The variants in CYP...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs-2019-0120
更新日期:2020-01-01 00:00:00
abstract::Aim: The need for pharmacogenomic education is becoming more and more urgent. Our aim was to evaluate the progress in pharmacogenomics education since then, and to put forward further recommendations. Methods: A survey was sent to 248 schools of medicine, pharmacy, nursing and health professions around the world. Resu...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs-2019-0009
更新日期:2019-06-01 00:00:00
abstract:BACKGROUND:Patients with mild-to-moderate essential hypertension in the HOMED-BP trial were randomly allocated to first-line treatment with a calcium channel blocker (CCB), angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB). METHODS:We recruited 265 (93 for CCB, 71 for ACEI and 101...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.13.161
更新日期:2013-11-01 00:00:00
abstract:INTRODUCTION:Most cancer pharmacogenetic studies use germline DNA, as tumor tissue is often inaccessible in the advanced disease setting. However, this relies on the assumption that germline DNA is representative of the tumor genotype. To date, there has been little attention paid to defining the relationship between t...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/14622416.6.8.873
更新日期:2005-12-01 00:00:00
abstract::Cost-effectiveness analysis is a widely used tool to assess the value of healthcare interventions. Our objective was to conduct a systematic review of the literature on the cost effectiveness of pharmacogenomic interventions. We found 11 studies that met our inclusion criteria. The most commonly examined disease was d...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.1517/14622416.5.8.1139
更新日期:2004-12-01 00:00:00
abstract:AIMS:Survivin (SVV) mRNA expression levels in peripheral blood of patients with gastrointestinal malignancies change significantly during the course of treatment. We wanted to scrutinize these findings in patients with esophageal carcinoma and furthermore evaluate whether the detection of mRNA and the change in detecti...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.09.164
更新日期:2010-03-01 00:00:00
abstract:AIM: HLA-B*15:02 screening should be performed to prevent antiepileptic drug induced severe cutaneous adverse reactions in populations of Asian origin. This study aimed to develop fast and reliable HLA-B*15:02 genotyping method and to investigate the distribution of HLA-B*15:02 in different Chinese ethnicities. MATERI...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs-2017-0041
更新日期:2017-06-01 00:00:00
abstract:AIM:Several HLA alleles have been associated with antiepileptic drugs (AEDs)-induced cutaneous adverse drug reactions (cADRs) in different populations; however, this has not been investigated in Mexican Mestizos (MM). Thus, the purpose of this preliminary study was to determine the association of HLA class I alleles wi...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.14.135
更新日期:2014-01-01 00:00:00
abstract::In the growing field of genomics, the utility of returning certain research results to participants has become a highly debated issue. Existing guidelines are not explicit as to the kind of genomic information that should be returned to research participants. Moreover, very few current recommendations and articles in ...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.2217/pgs.13.50
更新日期:2013-04-01 00:00:00
abstract::Damage to the heart can result from both traditional chemotherapeutic agents, such as doxorubicin, and newer 'targeted' therapies, such as trastuzumab. This chemotherapeutic cardiotoxicity is potentially life-threatening and necessitates limiting or discontinuing an otherwise-effective cancer treatment. Clinical strat...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.2217/pgs.12.205
更新日期:2013-01-01 00:00:00